UBS Initiates Coverage On ACADIA Pharmaceuticals with Buy Rating, Announces Price Target of $33
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Ashwani Verma has initiated coverage on ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy rating and a price target of $33.
October 17, 2023 | 11:47 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
UBS has initiated coverage on ACADIA Pharmaceuticals with a Buy rating and a price target of $33, which could positively impact the stock.
The initiation of coverage by UBS with a Buy rating indicates a positive outlook for ACADIA Pharmaceuticals. The price target of $33 suggests that the analyst believes the stock has significant upside potential. This could lead to increased investor interest and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100